You did the research. You found the money. You probably talked yourself out of it two or three times before finally committing. You flew somewhere, trusted strangers, surrendered a full day (or two, or three) to one of the most intense experiences a human body can have.
And then… not much.
Maybe the visionary experience was thin. Maybe your cravings came back in week two. Maybe you felt okay for a month and then found yourself right back where you started. Maybe you just feel the same.
Now you’re searching the internet for something honest, and you’re finding nothing. Testimonials from people who had breakthroughs. Clinics talking about “transformation.” The same three success stories recycled across a dozen websites.
Here’s the honest version.
Non-response is real, and no one publishes the numbers
Let’s start with the thing no one says plainly: ibogaine doesn’t work for everyone, every time. The published research is heavily skewed toward responders. Studies get funded and written up when outcomes are interesting. Clinics don’t publish their non-response rates. Advocates don’t talk about failure because it undercuts the case they’re trying to make. The result is a literature that systematically overstates how reliably ibogaine works.
This is a selection bias problem, not a conspiracy. But the effect is the same: if your session didn’t deliver what you hoped for, the internet gives you almost nothing to orient around.
So let’s orient.
What “didn’t work” actually means (and why it matters)
“Didn’t work” covers a lot of ground. It’s worth being specific about what you experienced, because the cause and the path forward are different depending on the answer.
The most common versions:
The experience was muted or absent. No significant visionary content, no emotional processing, no sense of the “flood” people describe. You were awake for 12 hours and it felt more like a strange, uncomfortable night than anything profound.
Mine fit that description, at least on the surface. I had tracers. Some open-eyed visual disturbances. But the closed-eye visions (the flood, the full immersive experience the literature describes) were absent. My expectations had been set by a documentary (In the Waves and War), which captures the full psychedelic intensity of an ibogaine experience. Walking into my own session with that as the frame of reference, and walking out with tracers, I felt like a failure. Like I had somehow done it wrong. The clinic staff had to talk me down. This is normal, they said. Not everyone has the visionary experience. The work is still happening. I didn’t entirely believe them. I’m writing this article partly because I now understand what they meant.
Cravings returned. You felt genuinely different in the first week or two, maybe even the first month. Then the pull came back, stronger than you expected.
Emotional state unchanged. Depression, anxiety, trauma responses: still there. Maybe slightly reorganized, but not touched in any meaningful way.
Relapse happened. This one carries the most shame, which is why it’s worth addressing directly: relapse after ibogaine treatment does not mean ibogaine failed you. It may mean the session genuinely did something neurologically (ibogaine is documented to reset opioid receptors and reduce acute withdrawal), but addiction has behavioral, social, and environmental components that a single session cannot touch. Returning to the same environment, the same people, the same stressors, with some degree of neurological reset but no structural change in your life, is a setup for relapse. That’s not an ibogaine failure. That’s an integration failure, and the distinction matters for what you do next.
My wife’s experience is a version of this. She went through ibogaine treatment, navigated a difficult stretch afterward, and then relapsed briefly. On the surface, that looks like failure. It felt like failure. But something had shifted underneath that the relapse obscured. After it, things started to click in a way they hadn’t before. She has been sober since. The relapse turned out to be part of the process, not the end of it. I don’t share that to offer false comfort. I share it because the shape of “it worked” is not always what you expect, and the timing is not always what you expect either.
The first four weeks are not always the right window
This is something practitioners say that rarely makes it into the promotional materials: ibogaine integration is not linear, and some people take months to understand what happened to them in the session.
If you’re evaluating your outcome at three weeks and it feels like nothing changed, that may be an accurate read. It may also be too soon. The neurological effects of ibogaine (particularly around BDNF, the protein associated with neural plasticity) appear to persist for weeks to months. Some people report a “delayed bloom”: a gradual shift in perspective, craving intensity, or emotional access that they didn’t register as a result of the session until much later.
None of this means you should dismiss what you’re feeling. If your experience was genuinely muted, that’s important information. But if you had some experience and it feels like it’s fading, or you’re in early relapse and trying to assess from that vantage point, give the window more room.
Why non-response happens: what the evidence suggests
Here are the factors that actually matter, based on what’s in the research and what experienced practitioners observe.
Underdosing. This one surprises people. Ibogaine dosing is based on body weight and is adjusted based on the individual, but there is real pressure on clinics (particularly those operating at legal margins) to stay conservative for safety reasons. A subtherapeutic dose can produce a mild experience that looks like non-response. If you don’t know what dose you received and how it was calculated, that’s worth finding out.
SSRI interactions. This is probably the most underreported factor. SSRIs occupy serotonin receptors in ways that can blunt or effectively block ibogaine’s action. The standard protocol is to taper off SSRIs before treatment, typically for several weeks. Some patients weren’t told this. Some tapered partially but not fully. Some were on medications that interact differently than their clinic anticipated. If you were on an SSRI or similar medication at the time of your session, this is a serious candidate explanation and worth discussing with a knowledgeable practitioner.
CYP2D6 metabolism: what it actually means for the therapy. This one is more nuanced than it first appears and is probably the most important factor for people who had a flat or muted experience. Ibogaine is metabolized by the liver enzyme CYP2D6 into a compound called noribogaine. The two molecules behave very differently. Ibogaine is short-acting (half-life of roughly 4–7 hours) and is responsible for the acute psychedelic experience: the closed-eye visions, the flood, the dreamlike states. Noribogaine is long-acting (half-life of 24–48 hours) and is not psychoactive. No visions. But noribogaine is where most of the sustained therapeutic work happens: GDNF and BDNF upregulation, opioid receptor normalization, craving reduction. Research published in the Journal of Neuroscience identified GDNF (glial cell line-derived neurotrophic factor) as a key mechanism behind ibogaine’s anti-addictive effects, and these neurotrophic effects appear to persist for weeks to months after the compounds have cleared.
Ultra-rapid CYP2D6 metabolizers (a genetic variant affecting roughly 5–10% of the population) convert ibogaine to noribogaine faster than average. The ibogaine clears before it can produce the full visionary experience. But the noribogaine is still there, still active, still doing the neurological work. If your session felt flat, fast metabolism is a real candidate explanation. And if it is: the rewiring may have happened anyway, without the flood. The absence of the visions is not the same as the absence of the therapy. This can be tested with a genetic CYP2D6 panel. If you’ve noticed other substances wearing off unusually quickly, it’s worth looking into.